Select Publications


Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Proc ASCO 2011;Abstract LBA1005.


Ruiz-Borrego M et al. Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts). *Proc ASCO* 2011;Abstract 1022.


Von Minckwitz G et al. Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). *San Antonio Breast Cancer Symposium* 2010;Abstract S4-6.


**CALGB-40502/NCCTG N063H: A Phase III trial of bevacizumab with paclitaxel, nab paclitaxel or ixabepilone in patients with Stage IIIIC-IV breast cancer. NCT00785291.**

**CALGB-40603 — Paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide in treating patients with breast cancer that can be removed by surgery. NCT00861705.**